Safety and efficacy of osimertinib 160 mg daily given concurrently with a strong CYP3A4 inducer
{{output}}
Introduction: Osimertinib remains the standard first-line therapy for patients with advanced EGFR-mutant NSCLC, at least in part due to its improved CNS penetrance compared to earlier generation EGFR TKIs. Strong CYP3A4-inducing ... ...
